Zacks: Analysts Anticipate Voyager Therapeutics Inc (VYGR) to Post -$0.76 Earnings Per Share

Share on StockTwits

Equities analysts forecast that Voyager Therapeutics Inc (NASDAQ:VYGR) will announce earnings per share of ($0.76) for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Voyager Therapeutics’ earnings. The highest EPS estimate is ($0.46) and the lowest is ($0.91). Voyager Therapeutics posted earnings per share of ($0.89) in the same quarter last year, which suggests a positive year-over-year growth rate of 14.6%. The company is expected to announce its next earnings results on Thursday, November 1st.

On average, analysts expect that Voyager Therapeutics will report full-year earnings of ($3.12) per share for the current financial year, with EPS estimates ranging from ($3.41) to ($2.43). For the next year, analysts expect that the business will report earnings of ($3.39) per share, with EPS estimates ranging from ($4.29) to ($2.60). Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Voyager Therapeutics.

Voyager Therapeutics (NASDAQ:VYGR) last posted its earnings results on Tuesday, August 7th. The company reported ($0.80) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.13). The business had revenue of $2.58 million for the quarter, compared to analyst estimates of $3.00 million. Voyager Therapeutics had a negative net margin of 731.88% and a negative return on equity of 80.68%.

VYGR has been the topic of several recent research reports. Morgan Stanley lowered shares of Voyager Therapeutics from an “overweight” rating to an “equal” rating in a report on Monday, September 10th. BidaskClub lowered shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, September 8th. Zacks Investment Research upgraded shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 11th. BTIG Research restated a “buy” rating and set a $32.00 target price on shares of Voyager Therapeutics in a report on Monday, September 10th. Finally, ValuEngine lowered shares of Voyager Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Monday, September 17th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Voyager Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $30.70.

Shares of NASDAQ:VYGR traded up $0.43 during midday trading on Friday, hitting $16.13. 256,414 shares of the company’s stock traded hands, compared to its average volume of 412,275. The firm has a market capitalization of $613.69 million, a price-to-earnings ratio of -6.11 and a beta of 2.94. Voyager Therapeutics has a twelve month low of $11.54 and a twelve month high of $31.91.

In other news, Director James A. Geraghty purchased 3,000 shares of the company’s stock in a transaction that occurred on Monday, September 10th. The shares were purchased at an average price of $19.39 per share, with a total value of $58,170.00. Following the purchase, the director now directly owns 76,588 shares of the company’s stock, valued at approximately $1,485,041.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Glenn Pierce purchased 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 12th. The shares were purchased at an average cost of $18.44 per share, for a total transaction of $92,200.00. The disclosure for this purchase can be found here. Insiders have purchased a total of 11,000 shares of company stock worth $205,300 in the last ninety days. 33.60% of the stock is currently owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in the stock. BB Biotech AG increased its stake in Voyager Therapeutics by 27.1% during the 2nd quarter. BB Biotech AG now owns 2,532,641 shares of the company’s stock worth $49,488,000 after buying an additional 540,000 shares during the period. BlackRock Inc. increased its stake in Voyager Therapeutics by 28.3% during the 2nd quarter. BlackRock Inc. now owns 1,845,706 shares of the company’s stock worth $36,066,000 after buying an additional 407,677 shares during the period. Farallon Capital Management LLC increased its stake in Voyager Therapeutics by 35.9% during the 1st quarter. Farallon Capital Management LLC now owns 890,000 shares of the company’s stock worth $16,723,000 after buying an additional 235,188 shares during the period. Millennium Management LLC increased its stake in Voyager Therapeutics by 124.0% during the 1st quarter. Millennium Management LLC now owns 618,021 shares of the company’s stock worth $11,613,000 after buying an additional 342,148 shares during the period. Finally, Wells Fargo & Company MN increased its stake in Voyager Therapeutics by 15.2% during the 2nd quarter. Wells Fargo & Company MN now owns 450,480 shares of the company’s stock worth $8,802,000 after buying an additional 59,497 shares during the period. 89.64% of the stock is currently owned by hedge funds and other institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.

Featured Story: What is intrinsic value?

Get a free copy of the Zacks research report on Voyager Therapeutics (VYGR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply